People: Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

25 Jul 2014
Price Change (% chg)

$-0.51 (-0.30%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Lavigne, Louis 

Brief Biography

Mr. Louis J. Lavigne, Jr.,is Independent Director of Allergan Inc. He is Managing Director of Lavrite, LLC, a management consulting firm in the areas of corporate finance, accounting, management and strategy since March 2005. Prior to these consulting activities, Mr. Lavigne served as Executive Vice President and Chief Financial Officer of Genentech, Inc., a publicly-traded biotechnology company, from March 1997 through his retirement in March 2005. Mr. Lavigne joined Genentech in July 1982, was named controller in 1983 and, in that position, built Genentech’s operating financial functions. In 1986, he was promoted to Vice President and assumed the position of Chief Financial Officer in September of 1988. Mr. Lavigne was named Senior Vice President in 1994 and was promoted to Executive Vice President in 1997. Prior to joining Genentech, he held various financial management positions with Pennwalt Corporation, a pharmaceutical and chemical company. Mr. Lavigne serves on the board of BMC Software, Inc., and is Chairman of its Audit Committee, and Accuray Incorporated. Mr. Lavigne also serves on the boards of SafeNet Inc., and Novocure Limited, a privately-held oncology company, where he serves as Chairman of the Audit Committee. Mr. Lavigne is a trustee of Children’s Hospital Oakland, where he serves as a member of its Finance and Compensation Committee. Mr. Lavigne is a faculty member of the Babson College Executive Education’s Bio-Pharma: Mastering the Business of Science program. Mr. Lavigne is also a trustee of Babson College and Babson Global and the Seven Hills School. Mr. Lavigne is a former member of the board and Chairman of the Audit Committees of Arena Pharmaceuticals, Equinix, Inc. and Kyphon, Inc. Mr. Lavigne is also a former Trustee of the California Institute of Technology. Mr. Lavigne was appointed to Board in July 2005 and is a member of the Audit and Finance Committee and the Science & Technology Committee.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Pyott


Douglas Ingram


Jeffrey Edwards


Scott Whitcup


Arnold Pinkston


Scott Sherman

As Of 30 Dec 2013
Search Stocks